Kymera Therapeutics (NASDAQ:KYMR) Reaches New 1-Year High at $49.06

Kymera Therapeutics, Inc. (NASDAQ:KYMR) reached a new 52-week high on Wednesday . The company traded as high as $49.06 and last traded at $48.52, with a volume of 410718 shares traded. The stock had previously closed at $46.50.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $46.00 target price on shares of Kymera Therapeutics in a research note on Monday, June 17th. Wells Fargo & Company lifted their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. B. Riley boosted their target price on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, July 9th. Oppenheimer reaffirmed an “outperform” rating and set a $52.00 target price on shares of Kymera Therapeutics in a research note on Wednesday, July 10th. Finally, Morgan Stanley lifted their price target on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a report on Wednesday, August 14th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.90.

Kymera Therapeutics Stock Up 4.4 %

The company has a 50 day simple moving average of $38.58 and a two-hundred day simple moving average of $37.70. The company has a market capitalization of $2.98 billion, a P/E ratio of -19.55 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. The firm had revenue of $25.60 million for the quarter, compared to the consensus estimate of $12.55 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The company’s revenue for the quarter was up 55.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.67) EPS. As a group, research analysts expect that Kymera Therapeutics, Inc. will post -2.86 EPS for the current fiscal year.

Insider Activity

In related news, Director Joanna Horobin sold 8,500 shares of Kymera Therapeutics stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Bruce Booth sold 16,740 shares of Kymera Therapeutics stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total transaction of $593,433.00. Following the completion of the sale, the director now directly owns 803,792 shares in the company, valued at $28,494,426.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Joanna Horobin sold 8,500 shares of the firm’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 502,345 shares of company stock valued at $19,279,932. 15.82% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently modified their holdings of the stock. Quest Partners LLC purchased a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $78,000. Comerica Bank lifted its holdings in shares of Kymera Therapeutics by 13.7% in the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after buying an additional 400 shares during the period. Public Employees Retirement Association of Colorado bought a new position in shares of Kymera Therapeutics during the 2nd quarter worth $139,000. Ameritas Investment Partners Inc. increased its stake in shares of Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after buying an additional 295 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Kymera Therapeutics during the second quarter valued at $201,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.